Retatrutide is the one everyone is watching. It is an experimental Eli Lilly drug that hits three receptors at once, and its trial weight-loss numbers are the highest anyone has reported for a weight-loss drug. It is also not approved, and anything sold as retatrutide today is gray-market. That combination, huge promise and no approval, is exactly why it needs a careful page.
Unusual for this site. Retatrutide has real, high-quality human trials, including a large Phase 3 program, so the efficacy data are strong. What it does not have is an approval or any long-term safety record, because it is still in testing. So the honest read is: the numbers are real and impressive, but the drug is unfinished.
Retatrutide is a single peptide that agonizes three receptors: GLP-1, GIP, and glucagon. People call it a “triple G” agonist. It is a once-weekly injection with about a six-day half-life. Lilly’s internal code is LY3437943.
Lilly designed it in the late 2010s and moved fast. Phase 1 established weekly dosing, a Phase 2 obesity trial published in 2023 produced eye-popping results, and a large Phase 3 program (called TRIUMPH) has been reporting through 2025 and 2026.
The GLP-1 and GIP arms do what tirzepatide’s do, reducing appetite and improving insulin response. The third arm is the difference. Glucagon-receptor agonism is thermogenic and fat-mobilizing. In plain terms, it is thought to raise energy expenditure and to burn fat in the liver directly, which adds to the appetite reduction from the other two arms. That glucagon arm is the leading explanation both for the exceptional liver-fat results and for a couple of retatrutide-specific side effects.
There is no approved use yet. In trials it is being studied for obesity, diabetes, fatty-liver disease, sleep apnea, osteoarthritis of the knee, and cardiovascular and kidney outcomes. Gray-market use is for weight loss.
The gastrointestinal effects are the usual ones, worst during dose escalation, and much worse if the titration steps are skipped. Two effects stand out with retatrutide. It causes a dose-dependent rise in resting heart rate, on the order of a few beats per minute at higher doses, which peaked and then eased in trials. And it causes a skin tingling or burning sensation, called dysesthesia. In most Phase 3 trials it affected roughly 2% to 13% of people, depending on dose. The highest rate so far was 20.9% at 12 mg in TRIUMPH-4, the knee osteoarthritis trial. It is not a typical feature of the GLP-1-only or dual drugs, and its exact cause is not yet clear.
The bigger caveat is simple. There is no long-term safety data because the drug is not approved. Class-level concerns like pancreatitis, gallbladder effects, the rodent thyroid signal, and muscle loss are plausible but not yet established for retatrutide specifically.
Read this as trial data and reporting, not a recommendation. In the Phase 3 program the dose is started low, at 2 mg, and stepped up every four weeks toward targets of 4, 9, or 12 mg, so reaching the top dose takes roughly four to five months. Slower titration clearly reduced the nausea. Community and gray-market figures echo those trial numbers, but they come from unregulated products of unverified content, and there is no approved label, so there is no established safe way to self-administer it. This site does not give injection instructions.
Not approved anywhere, as of September 2026. Lilly announced plans to file with the FDA around the first quarter of 2027, which puts a possible approval in the late 2027 to 2028 window if the review goes well. There is also a narrow pre-approval expanded-access program for severely affected patients who cannot join a trial, requested by a physician. That is compassionate access, not general availability. Everything sold to the public now is gray-market and not the reviewed drug.
Semaglutide hits one receptor and gets you around 15%. Tirzepatide hits two and gets around 20%. Retatrutide hits three and got about 24 to 28% in trials. So the pattern of “more receptors, more weight loss” holds. The catches are that retatrutide is not a head-to-head winner yet (a direct comparison against tirzepatide is expected around the end of 2026), it is not approved, and its safety over years is unknown.
Is retatrutide FDA-approved? No. It is investigational. Lilly plans to file around early 2027, with possible approval in the 2027 to 2028 range if the review succeeds.
How much weight did people lose? About 24% at 48 weeks in Phase 2, and about 28% at 80 weeks at the top dose in Phase 3.
What makes it different from the others? It adds a third receptor, glucagon, which is thought to raise energy expenditure and burn liver fat directly, not just cut appetite.
What is the skin-tingling side effect? Dysesthesia, an abnormal skin sensation tied to the glucagon arm, usually reported in roughly 2% to 13% of people in Phase 3, and up to 20.9% at the top dose in one trial.
Can I get it legally now? Not as an approved medicine. A narrow physician-requested expanded-access program exists for severe cases. Products sold online are unregulated gray-market.
Is it safe? Its long-term safety is unknown because it is not approved and has no post-market record.
Plain-language updates on new research and the shifting rules. No hype, unsubscribe anytime.